Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.58 CHF | +4.61% | +8.59% | +21.81% |
03/05 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
09/04 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.81% | 542M | |
+20.48% | 46.4B | |
-1.05% | 41.75B | |
+47.75% | 41.37B | |
-3.52% | 29.71B | |
+10.30% | 26.01B | |
-19.90% | 19.52B | |
+30.13% | 12.43B | |
+0.32% | 12.18B | |
-0.27% | 12.13B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica Plans Early Repayment of Loan from Athyrium Capital